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ABSTRACT cell biology is one of the most rapidly developing branches in modern biology. the most interesting stages in early embryonic development for cell 
biology are those when a large number of cells are pluripotent. Inner-cell mass of blastocyst can be cultivated in vitro, and these cells are called embryonic stem 
cells. they are able to differentiate into different types of cells and tissues. But the greatest interest for practical application is the return (reprogramming) of 
adult cells into the pluripotent state. In our study for the first time induced pluripotent cells were derived from human umbilical vein endothelial cells by genetic 
reprogramming. We showed that these cells are similar to embryonic stem cells in their morphology, function, and molecular level. We are the first to show that 
reprogramming sufficiently changes X-chromosome chromatin state, which is normally inactive in female endothelial cells, towards its activation, providing 
evidence that endothelial cells are reprogrammed at an epigenetic level.
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A 
multicellular organism develops from a single cell, 
a zygote, and becomes a complex of mutually sup-
ported tissue types during its individual develop-
ment. the totipotent zygote cell and the terminally differ-
entiated cell contain the same set of genetic information, but 
this information is achieved differently. cellular programs of 
differentiation happen at the genetic and epigenetic levels. 
the zygote achieves a specified program and divides, and at 
a certain stage, cells begin to specialize. A blastocyst (about 
3.5 days in mouse and 5.5 days in humans) has two types of 
cells and is a future embryo which has no physical connection 
with its mother’s organism. the inner cells will develop into 
the organism and all its tissues, and the outer layer of cells 
will develop into trophectogerm, which will interact with the 
mother’s organism. In vitro (in laboratory conditions) culti-
vated blastocyst inner-cell mass were called embryonic stem 
cells (eSc). In vitro eSc under appropriate conditions do not 
continue their program further; they stay in a pluripotent 
state for an unlimited time [1], but one can induce their con-
trolled differentiation into the tissues of all three germ layers 
just by changing the culture’s conditions [2]. However, in the 
case of using these type of cells in therapy, the immunologic 
compatibility between the derived tissues and the recipient 
remains to be defined. reprogramming individual somatic 
cells to a pluripotent state will be a perfect solution to this 
problem. For this purpose, the technologies of somatic cell 
nuclear transfer into the oocyte and fusion of the somatic cell 
with the pluripotent one were developed [3–5]. However, 
in 2006, S. Yamanaka [6] put forward a method of somatic 
cell genetic reprogramming to the pluripotent state. For the 
induction of the pluripotent state, genes which encode the 
transcriptional factors essential for early embryonal devel-
opment and maintenance of the pluripotent state Oct3/4 and 
Sox2, the antiapoptopic transcriptional factor Klf4, and the 
transcriptional factor, which maintain the cell’s proliferation 
c-Myc, were used. these cells were called induced pluripo-
tent stem (iPS) cells. In the last three years, this technology 
has been significantly improved and doesn’t require obliga-
tory genetic modification [7–9]. But the number of human cell 
types that were successfully reprogrammed remained very 
restricted [10, 11].
cells which are able to generate iPS cells should have some 
distinct features. First, they should be sensitive to total re-
programming. Second, they should be available. third, they 
should not have any accumulated DnA damage, for example, 
uV or other environmental skin-cell damage. And finally, the 
number of cells should be sufficient, and the reprogramming 
effective enough to minimize all possible DnA damage during 
in vitro manipulations. Based on the above-mentioned crite-
ria, our aims were to choose an optimal cell type and geneti-
cally reprogram these cells to optimize their further use.
We decided to take human umbilical vein cells for repro-
gramming. they can be easily obtained; have not accumu-
lated any DnA damage; can be obtained in large amounts 
without cultivation, proliferate well in culture only in the 
presence of factors that maintain their growth; and, in con-
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Fig. 1. Morphology of iPS derived from an endothelium, feeder-free 
culture. A – Bright field image of iPS colony. B – Image of ESC colony. 
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junction with the development of umbilical vein banks, they 
can be stored for a long time. there is no data in the litera-
ture about endothelial-cell reprogramming. the reprogram-
ming was achieved by the use of genetic constructs which 
were tested in earlier experiments [6]. Human umbilical vein 
endothelial cells (HuVec) were transducted with retroviral 
vectors which contained cDnA of Oct3/4, Sox2, KLF4 and 
cMyc genes. the multiplicity of infection was five viral par-
ticles. Six days after infection, the endothelial-cell culture 
medium was changed to an eSc medium. It is worth noting 
that endothelial cells do not proliferate in an eSc culture 
medium; this significantly enabled the selection of iPS cells. 
three weeks after viral infection, morphologically identical 
eSc clones were selected (Fig 1).
the derived iPS cells did not differ in their the prolifera-
tive or morphological characteristics from human eScs (Figs 
2a, 2b). We confirmed with fingerprinting that these iPS were 
generated from human umbilical vein endothelial cells se-
lected for reprogramming and were not the result of cellular 
culture contamination with human eS cells. to determine 
the number of integrated pro-virus copies, we used genomic 
hybridization with specific probes. copy number varied from 
two to three copies of each virus per genome in derived iPS 
lines. these human iPS cells were pluripotent, formed em-
bryonic bodies (Fig 2c), and differentiated into derivatives 
of all three germ layers. A karyotype analysis demonstrated 
that reprogrammed cells have a normal karyotype and retain 
it for at least 22 passages. iPS cells were cultivated in feeder-
free conditions in a mteSr1-defined medium. thus, we are 
the first to obtain iPS cells from human endothelium free of 
animal-derived components. the developed method allows us 
to obtain clinically applicable iPS cell lines.  
Apart from changes in the realization of the genetic, pro-
gram significant changes in the epigenetic state of somatic 
cells should take place during reprogramming. Inactivation of 
one of the two X-chromosomes in female cells occurs during 
early emryogenesis, although both X-chromosomes can be 
active in eScs. consequently, one can expect that during re-
programming there would be functional changes resulting in 
the reactivation of the inactive X-chromosome in endothelial 
cells. We used antibodies to active (H3me2K4) and nonactive 
(H3me3K27) chromatin to conduct an immunocytochemical 
analysis of X-chromosomes in derived iPS cell lines. Our data 
revealed that the marker of active chromatin (H3me2K4) ap-
pears on the nonactive X-chromosome in iPS cells (Fig 2d); at 
the same time, inactive chromosome in endothelial cells lacks 
an expression of this marker. therefore, we are the first to 
show that, during genetic reprogramming, the reactivation of 
the inactive X-chromosome occurs in human cells. Our find-
ings show that human endothelial cells can be effectively and 
completely reprogrammed to the pluripotent state, which 
was confirmed by morphological, molecular, and functional 
tests.
It is obvious that further experiments should be carried 
out for iPS cells application: for example, to confirm the re-
programmed state on the genome level and to confirm the 
oncogenic safety of iPS cells. this kind of research is one of 
the most promising avenues in the sphere of cell technolo-
gies. However, one should not forget that iPS cells are only 
an artificial analogue of eScs: therefore, in order to identify 
their significance for application, two groups of pluripotent 
cells should be studied. 
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Fig. 2. Feature analysis of human iPS cells derived from human umbilical vein endothelial cells. A, B – immunohistochemical analysis of iPS cells, 
antibodies stain to specific markers of pluripotency Oct4 (A) and SSEA-4 (B). The specific signals are stained with green (A) and red (B), nuclei in (B) 
are stained with blue (DAPI). C – embryonic bodies, derived from iPS cultured in suspension. Bar scale – 100 mkm. D – interphase nucleus in iPS cells 
stained with active chromatin marker H3me2K4 (red). White arrows localize the chromosome region of partly reactivated X – chromosome
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